CY1120536T1 - Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου - Google Patents
Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινουInfo
- Publication number
- CY1120536T1 CY1120536T1 CY20181100285T CY181100285T CY1120536T1 CY 1120536 T1 CY1120536 T1 CY 1120536T1 CY 20181100285 T CY20181100285 T CY 20181100285T CY 181100285 T CY181100285 T CY 181100285T CY 1120536 T1 CY1120536 T1 CY 1120536T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compositions
- health education
- cancer health
- cancer
- subject
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001495 arsenic compounds Chemical class 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3998708P | 2008-03-27 | 2008-03-27 | |
| US12/408,864 US20090246291A1 (en) | 2008-03-27 | 2009-03-23 | Method and compositions for treatment of cancer |
| PCT/US2009/038104 WO2009120697A2 (en) | 2008-03-27 | 2009-03-24 | Method and compositions for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120536T1 true CY1120536T1 (el) | 2019-07-10 |
Family
ID=41114644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100285T CY1120536T1 (el) | 2008-03-27 | 2018-03-09 | Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20090246291A1 (https=) |
| EP (1) | EP2268292B1 (https=) |
| JP (2) | JP5543956B2 (https=) |
| KR (1) | KR101634138B1 (https=) |
| CN (2) | CN104997808A (https=) |
| AU (1) | AU2009228378B2 (https=) |
| BR (1) | BRPI0909164A2 (https=) |
| CA (1) | CA2719766C (https=) |
| CY (1) | CY1120536T1 (https=) |
| DK (1) | DK2268292T3 (https=) |
| ES (1) | ES2656762T3 (https=) |
| HU (1) | HUE036609T2 (https=) |
| LT (1) | LT2268292T (https=) |
| MX (1) | MX2010010621A (https=) |
| PL (1) | PL2268292T3 (https=) |
| PT (1) | PT2268292T (https=) |
| RU (1) | RU2508116C2 (https=) |
| SI (1) | SI2268292T1 (https=) |
| WO (1) | WO2009120697A2 (https=) |
| ZA (1) | ZA201006988B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| PT2475362T (pt) * | 2009-09-10 | 2019-05-27 | Kominox Inc | Terapia especifica para celulas estaminais cancerigenas e para 0 cancro resistente a medicamentos |
| US8795738B2 (en) * | 2009-11-12 | 2014-08-05 | Board Of Regents Of The University Of Texas System | Use of arsenic for cancer therapy protection |
| US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| CN103153303A (zh) * | 2010-07-18 | 2013-06-12 | 尼基制药公司 | 使用钌络合物的联合疗法 |
| ES2718637T3 (es) * | 2010-08-24 | 2019-07-03 | Gtx Inc | Compuestos para el tratamiento del cáncer |
| US20120251628A1 (en) * | 2011-03-30 | 2012-10-04 | Young Joo Min | Compositions and methods for treatment of cancer |
| CN103826645A (zh) * | 2011-05-12 | 2014-05-28 | 得克萨斯系统大学评议会 | 砷在癌症治疗保护中的用途 |
| US8834938B2 (en) | 2011-05-18 | 2014-09-16 | Board Of Regents Of The University Of Texas System | Use of arsenic for cancer therapy protection |
| KR101309844B1 (ko) | 2013-03-15 | 2013-09-23 | 박상채 | 항암 활성 증진용 한약재 및 이의 제조방법 |
| WO2014152330A1 (en) * | 2013-03-15 | 2014-09-25 | Stc.Unm | Arsenic-based treatment of cancers and inflammatory disorders |
| MX372671B (es) * | 2013-07-19 | 2020-04-23 | Onyx Therapeutics Inc | Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres. |
| ES2964979T3 (es) | 2016-12-01 | 2024-04-10 | Eupharma Pty Ltd | Composiciones de arsénico |
| AU2019239671B2 (en) | 2018-03-22 | 2025-02-27 | Komipharm International Australia Pty Ltd | Pharmaceutical composition comprising meta arsenite and method of manufacture |
| CN116236505A (zh) * | 2023-03-15 | 2023-06-09 | 上海市第四人民医院 | 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001519366A (ja) * | 1997-10-15 | 2001-10-23 | ポーラクス バイオファーマシュティカルズ，インコーポレーテッド | ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法 |
| IL136051A0 (en) * | 1997-11-10 | 2001-05-20 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
| EP1496918B1 (en) * | 2002-04-10 | 2023-02-08 | Komipharm International Co., Ltd. | Use of sodium meta-arsenite for the treatment of tumours |
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8097237B2 (en) * | 2005-08-23 | 2012-01-17 | Stc.Unm | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
| US7867492B2 (en) * | 2007-10-12 | 2011-01-11 | The John Hopkins University | Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies |
-
2009
- 2009-03-23 US US12/408,864 patent/US20090246291A1/en not_active Abandoned
- 2009-03-24 RU RU2010143893/15A patent/RU2508116C2/ru active
- 2009-03-24 DK DK09723788.7T patent/DK2268292T3/en active
- 2009-03-24 WO PCT/US2009/038104 patent/WO2009120697A2/en not_active Ceased
- 2009-03-24 MX MX2010010621A patent/MX2010010621A/es active IP Right Grant
- 2009-03-24 CN CN201510355863.5A patent/CN104997808A/zh active Pending
- 2009-03-24 JP JP2011501983A patent/JP5543956B2/ja not_active Expired - Fee Related
- 2009-03-24 AU AU2009228378A patent/AU2009228378B2/en not_active Ceased
- 2009-03-24 CN CN2009801187686A patent/CN102046187A/zh active Pending
- 2009-03-24 EP EP09723788.7A patent/EP2268292B1/en active Active
- 2009-03-24 BR BRPI0909164A patent/BRPI0909164A2/pt not_active Application Discontinuation
- 2009-03-24 LT LTEP09723788.7T patent/LT2268292T/lt unknown
- 2009-03-24 KR KR1020107024132A patent/KR101634138B1/ko not_active Expired - Fee Related
- 2009-03-24 PT PT97237887T patent/PT2268292T/pt unknown
- 2009-03-24 CA CA2719766A patent/CA2719766C/en active Active
- 2009-03-24 HU HUE09723788A patent/HUE036609T2/hu unknown
- 2009-03-24 SI SI200931809T patent/SI2268292T1/en unknown
- 2009-03-24 PL PL09723788T patent/PL2268292T3/pl unknown
- 2009-03-24 ES ES09723788.7T patent/ES2656762T3/es active Active
-
2010
- 2010-09-30 ZA ZA2010/06988A patent/ZA201006988B/en unknown
-
2014
- 2014-03-10 JP JP2014046212A patent/JP2014101387A/ja not_active Withdrawn
-
2017
- 2017-06-02 US US15/613,020 patent/US20180055812A1/en not_active Abandoned
-
2018
- 2018-03-09 CY CY20181100285T patent/CY1120536T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE036609T2 (hu) | 2018-07-30 |
| AU2009228378A1 (en) | 2009-10-01 |
| JP5543956B2 (ja) | 2014-07-09 |
| WO2009120697A3 (en) | 2010-02-18 |
| US20090246291A1 (en) | 2009-10-01 |
| MX2010010621A (es) | 2011-04-05 |
| ES2656762T3 (es) | 2018-02-28 |
| WO2009120697A2 (en) | 2009-10-01 |
| CN104997808A (zh) | 2015-10-28 |
| EP2268292A2 (en) | 2011-01-05 |
| CA2719766C (en) | 2017-10-31 |
| SI2268292T1 (en) | 2018-03-30 |
| CA2719766A1 (en) | 2009-10-01 |
| KR20110009664A (ko) | 2011-01-28 |
| EP2268292A4 (en) | 2011-05-11 |
| PL2268292T3 (pl) | 2018-06-29 |
| LT2268292T (lt) | 2018-03-26 |
| KR101634138B1 (ko) | 2016-06-28 |
| AU2009228378B2 (en) | 2014-07-17 |
| US20180055812A1 (en) | 2018-03-01 |
| RU2010143893A (ru) | 2012-05-10 |
| RU2508116C2 (ru) | 2014-02-27 |
| WO2009120697A4 (en) | 2010-04-15 |
| CN102046187A (zh) | 2011-05-04 |
| PT2268292T (pt) | 2018-02-19 |
| DK2268292T3 (en) | 2018-03-12 |
| JP2011515481A (ja) | 2011-05-19 |
| ZA201006988B (en) | 2012-05-30 |
| JP2014101387A (ja) | 2014-06-05 |
| EP2268292B1 (en) | 2017-12-27 |
| BRPI0909164A2 (pt) | 2016-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120536T1 (el) | Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου | |
| CY1125772T1 (el) | Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων | |
| CY1124628T1 (el) | Συζευγματα αντισωματος-φαρμακου βασει εριβουλινης και μεθοδοι χρησεως | |
| CY1120547T1 (el) | Νανοσωματιδιο που περιλαμβανει ραπαμυκινη και αλβουμινη ως αντικαρκινικος παραγοντας | |
| CY1118216T1 (el) | Μεθοδοι αγωγης καρκινου | |
| CY1125077T1 (el) | Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3 | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
| CY1120102T1 (el) | Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CL2018002291A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221) | |
| CY1122074T1 (el) | Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις | |
| CY1117869T1 (el) | Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο | |
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| CY1124529T1 (el) | Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου | |
| CY1118081T1 (el) | Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| EA201690085A1 (ru) | Полимерные наночастицы доцетаксела для лечения рака | |
| CY1122998T1 (el) | Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη |